Clinical trial • Phase III • Oncology

ANITOCABTAGENE AUTOLEUCEL for Relapsed/refractory multiple myeloma

Phase III trial of ANITOCABTAGENE AUTOLEUCEL for Relapsed/refractory multiple myeloma.

Overview

Trial Therapeutic Area
Oncology
Trial Disease
Relapsed/refractory multiple myeloma
Trial Stage
Phase III
Drug Modality
Cell therapy|Monoclonal antibody|Small molecule
Orphan Drug
Yes

Key dates

Initial CTIS Submission Date
26-07-2024
First CTIS Authorization Date
09-12-2024

Trial design

Randomised, open-label, standard of care therapy (soct) chosen by investigator: one of pvd, dpd, kdd, or kd. comparator agents explicitly listed include darzalex (daratumumab), imnovid (pomalidomide), kyprolis (carfilzomib), bortezomib (bortezomib fresenius kabi), and neofordex (dexamethasone). doses and schedules are not specified in the ctis metadata.-controlled Phase III trial in Germany, Italy, Austria and others.

Randomised
Yes
Open Label
Yes
Comparator
Standard of care therapy (SOCT) chosen by investigator: one of PVd, DPd, KDd, or Kd. Comparator agents explicitly listed include DARZALEX (daratumumab), Imnovid (pomalidomide), Kyprolis (carfilzomib), Bortezomib (Bortezomib Fresenius Kabi), and Neofordex (dexamethasone). Doses and schedules are not specified in the CTIS metadata.
Target Sample Size
450

Eligibility

Recruits 450 Vulnerable population flag selected. Participants must be adults (18 years or older) and provide written informed consent. Separate informed consent forms are provided for pregnant participants, pregnant partners, caregivers, and for scout/telephone pre-ICF procedures (language- and country-specific ICFs are available). No paediatric assent procedures are included (study limited to adults)..

Pregnancy Exclusion
Females of childbearing potential must have a medically supervised negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
Vulnerable Population
Vulnerable population flag selected. Participants must be adults (18 years or older) and provide written informed consent. Separate informed consent forms are provided for pregnant participants, pregnant partners, caregivers, and for scout/telephone pre-ICF procedures (language- and country-specific ICFs are available). No paediatric assent procedures are included (study limited to adults).

Inclusion criteria

  • {"criterion_text":"- Documented historical diagnosis of MM"}
  • {"criterion_text":"- Received 1 to 3 prior lines of antimyeloma therapy, including an IMiD and an anti-CD38 mAb. A minimum of 2 consecutive cycles of an IMiD and an anti-CD38 mAb in any prior line of therapy is required. The IMiD and anti-CD38 mAb do not need to be from the same regimen in the prior line(s) of therapy."}
  • {"criterion_text":"- Documented evidence of progressive disease by IMWG criteria based on the investigator’s determination on or within 12 months of the last dose of the last regimen"}
  • {"criterion_text":"- Measurable disease at screening per IMWG, defined as any of the following: a) Serum M-protein level ≥ 0.5 g/dL or urine M-protein level ≥ 200 mg/24 hours; or b) Light chain MM without measurable disease in the serum or urine: serum free light chain ≥ 10 mg/dL and abnormal serum free light chain ratio"}
  • {"criterion_text":"- Only participants who are candidates to receive at least 1 of the 4 SOCT regimens (PVd, DPd, KDd, or Kd), as determined by the investigator, should be considered for this Study"}
  • {"criterion_text":"- Male or female aged 18 years or older and who have provided written informed consent"}
  • {"criterion_text":"- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1"}
  • {"criterion_text":"- Females of childbearing potential must have a medically supervised negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)"}

Exclusion criteria

  • {"criterion_text":"- Prior BCMA-targeted therapy"}
  • {"criterion_text":"- Prior T-cell engager therapy"}
  • {"criterion_text":"- Prior CAR therapy or other genetically modified T-cell therapy"}
  • {"criterion_text":"- Active or prior history of central nervous system (CNS) or meningeal involvement of MM"}
  • {"criterion_text":"- Cardiac atrial or cardiac ventricular MM involvement"}
  • {"criterion_text":"- History of or active plasma cell leukemia (defined as 5% circulating plasma cells per IMWG 2021 consensus definition , Waldenstrom’s macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or amyloidosis"}
  • {"criterion_text":"- Active malignancy (other than MM) requiring ongoing treatment for disease control within the last 24 months. Myelodysplastic syndrome (even without ongoing treatment) is not permitted."}
  • {"criterion_text":"- Prior auto-SCT within 12 weeks before randomization"}
  • {"criterion_text":"- Prior allogeneic stem cell transplant (allo-SCT)"}
  • {"criterion_text":"- High-dose (eg, cumulative > 70 mg prednisone or equivalent) systemic steroid therapy or any other form of immunosuppressive therapy within 14 days before randomization"}
  • {"criterion_text":"- Live vaccine ≤ 4 weeks before randomization"}
  • {"criterion_text":"- Contraindication to fludarabine or cyclophosphamide"}
  • {"criterion_text":"- History of allergy or hypersensitivity to any study agent or study drug components. Participants with a history of severe hypersensitivity reaction including anaphylaxis due to dimethyl sulfoxide (DMSO) or gentamicin are excluded."}
  • {"criterion_text":"- Life expectancy < 12 weeks"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- PFS, defined as the time to disease progression per IMWG criteria as determined by IRC, or death due to any cause, whichever occurs first","definition_or_measurement_approach":"Time to disease progression per IMWG criteria as determined by an Independent Review Committee (IRC), or death from any cause, whichever occurs first."}
  • {"endpoint_text":"- Minimal residual disease (MRD)-negative complete response (CR) rate at 9 months, defined as the proportion of participants achieving CR/stringent CR (sCR) and MRD-negative status at 9 months. MRD negativity at 9 months is defined as negative MRD value at 9 months (± 3 months) in bone marrow assessment (< 1 in 10^5 nucleated cells per IMWG criteria using NGS) {Kumar 2016}. CR/sCR per IMWG criteria is determined by IRC","definition_or_measurement_approach":"Proportion of participants achieving CR/sCR and MRD-negative status at 9 months (±3 months) by bone marrow assessment using NGS (<1 in 10^5 nucleated cells) per IMWG criteria; CR/sCR determined by Independent Review Committee (IRC)."}

Secondary endpoints

  • {"endpoint_text":"- Complete response (CR) rate (CR/stringent CR [sCR]) per IMWG criteria by IRC","definition_or_measurement_approach":"CR/sCR determined by Independent Review Committee (IRC) according to IMWG criteria."}
  • {"endpoint_text":"- Overall minimal residual disease (MRD) negativity (minimum 10^−5)","definition_or_measurement_approach":"MRD negativity assessed at sensitivity of at least 10^-5 (methodology: NGS as per protocol)."}
  • {"endpoint_text":"- Overall survival (OS)","definition_or_measurement_approach":"Time from randomization to death from any cause."}
  • {"endpoint_text":"- Overall response rate","definition_or_measurement_approach":"Proportion of participants achieving a predefined response per IMWG criteria."}
  • {"endpoint_text":"- MRD-negative CR/sCR and MRD-negative very good partial response (VGPR)+","definition_or_measurement_approach":"MRD-negative status combined with CR/sCR and MRD-negative VGPR+ as assessed by bone marrow NGS per IMWG criteria."}
  • {"endpoint_text":"- Sustained MRD negativity","definition_or_measurement_approach":"Duration of maintained MRD negativity as defined in protocol assessments."}
  • {"endpoint_text":"- Duration of response","definition_or_measurement_approach":"Time from first documented response to disease progression or death."}
  • {"endpoint_text":"- Time to progression","definition_or_measurement_approach":"Time from randomization to documented disease progression per IMWG criteria."}
  • {"endpoint_text":"- Time to next treatment","definition_or_measurement_approach":"Time from randomization to initiation of next line of antimyeloma therapy."}
  • {"endpoint_text":"- Incidence, seriousness, and severity of all adverse events (AEs)","definition_or_measurement_approach":"Standard AE reporting (incidence, seriousness, and severity) as captured in case report forms and safety reporting per protocol."}
  • {"endpoint_text":"- Levels of anti-anitocabtagene autoleucel chimeric antigen receptor (CAR) antibodies (anitocabtagene autoleucel arm)","definition_or_measurement_approach":"Measurement of anti-CAR antibody levels in participants receiving anitocabtagene autoleucel."}
  • {"endpoint_text":"- Presence of replication-competent lentivirus (RCL) (anitocabtagene autoleucel arm)","definition_or_measurement_approach":"Testing for replication-competent lentivirus in biospecimens from participants in the CAR-T arm."}
  • {"endpoint_text":"- Change from baseline quality of life scores across postbaseline assessment visits as measured by: European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire – Multiple Myeloma Module (EORTC QLQ-MY20). European Quality of Life 5-Dimension 5-Level Scale (EQ-5D-5L)","definition_or_measurement_approach":"Patient-reported outcome (PRO) instruments: EORTC QLQ-C30, EORTC QLQ-MY20, and EQ-5D-5L; change from baseline across scheduled post-baseline visits."}
  • {"endpoint_text":"- Frequency of hospitalizations, inpatient days, intensive care unit days, and reasons for hospitalization","definition_or_measurement_approach":"Health resource utilization measures collected during study follow-up (number and reasons for hospitalizations, inpatient and ICU days)."}

Recruitment

Digital Remote Recruitment
True, telephone-based pre-screening and consent support are described (documents include SC-telephone-Pre-ICF, Scout telephone consent, Telephone-Data-ICF and country-specific scout/telephone consent forms).
Planned Sample Size
450
Recruitment Window Months
82
Consent Approach
Written informed consent required from participants (study restricted to adults ≥18 years). Country- and language-specific main ICFs are provided (documents available in DE, FR, IT, NL, PL, CZ, ES, EN and others). Separate ICFs are available for pregnant participants, pregnant partners, caregivers, optional future research, telephone/scout pre-ICF and telephone data consent procedures.

Methods

  • Country-specific recruitment arrangements documents (K1) and patient recruitment flyers (K2) are used (documents available for DE, IT, AT, CZ, BE, ES, NL, PL, FR).
  • GP letters (country-specific; e.g. GP-Letter_IT) to primary care physicians to support referral (document present for Italy).
  • Site-based recruitment (site desk support and site materials) — trial sites listed per country; desk support provided by CRO/vendors (Medidata, PPD).
  • Pre-screening and scout telephone contact procedures (Scout and SC-telephone-Pre-ICF documents) to identify potential participants.

Geography

Total Number Of Sites
51
Total Number Of Participants
192

Germany

Earliest CTIS Part Ii Submission Date
16-10-2024
Latest Decision Or Authorization Date
23-02-2026
Processing Time Days
495
Number Of Sites
8
Number Of Participants
24

Sites

Site Name
University Medical Center Hamburg-Eppendorf
Department Name
II. Medizinische Klinik und Poliklinik
Contact Person Name
Katja Weisel
Contact Person Email
k.weisel@uke.de
Site Name
Medical Center - University Of Freiburg
Department Name
Klinik für Innere Medizin I, ITZ, Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation
Contact Person Name
Ralph Wäsch
Site Name
Universitaetsklinikum Wuerzburg AöR
Department Name
Medizinische Klinik und Poliklinik II
Contact Person Name
Johannes Waldschmidt
Contact Person Email
Waldschmid_J@ukw.de
Site Name
Universitaetsklinikum Essen AöR
Department Name
Klinik für Hämatologie und Stammzelltransplantation Westdeutsches Tumorzentrum Essen
Contact Person Name
Bastian von Tresckow
Site Name
Charite Universitaetsmedizin Berlin KöR
Department Name
Campus Benjamin Franklin (CBF) Med. Klinik m. Schwerpunkt Hämatologie, Onkologie u. Tumorimmunologie
Contact Person Name
Stephan Bohl
Contact Person Email
stephan.bohl@charite.de
Site Name
Universitaet Leipzig
Department Name
Klinik und Poliklinik für Hämatologie, Zelltherapie, Hämostaseologie und Infektiologie, Studieneinh
Contact Person Name
Vladan Vucinic
Site Name
Klinikum rechts der Isar der TU Muenchen AöR
Department Name
Klinik und Poliklinik für Innere Medizin III, Hämatologie/Onkologie
Contact Person Name
Judith Hecker
Contact Person Email
judith.hecker@mri.tum.de
Site Name
University Hospital Cologne AöR
Department Name
Klinik für Innere Medizin I
Contact Person Name
Tim Richardson
Contact Person Email
tim.richardson@uk-koeln.de

Italy

Earliest CTIS Part Ii Submission Date
16-10-2024
Latest Decision Or Authorization Date
17-02-2026
Processing Time Days
489
Number Of Sites
5
Number Of Participants
20

Sites

Site Name
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Department Name
UOC Ematologia
Contact Person Name
Elena Zamagni
Contact Person Email
e.zamagni@unibo.it
Site Name
Ospedale San Raffaele S.r.l.
Department Name
UOE-TMO
Contact Person Name
Fabio Ciceri
Contact Person Email
ciceri.clinicaltrials@hsr.it
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
Servizio e DH di Ematologia e Trapianto di cellule staminali
Contact Person Name
Valerio De Stefano
Contact Person Email
valerio.destefano@unicatt.it
Site Name
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Department Name
SC Ematologia U
Contact Person Name
Benedetto Bruno
Contact Person Email
Benedetto.bruno@unito.it
Site Name
Fondazione IRCCS Istituto Nazionale Dei Tumori
Department Name
S.C. Ematologia – Trapianto di Midollo Osseo Allogenico
Contact Person Name
Paolo Corradini
Contact Person Email
paolo.corradini@unimi.it

Austria

Earliest CTIS Part Ii Submission Date
08-11-2024
Latest Decision Or Authorization Date
17-02-2026
Processing Time Days
466
Number Of Sites
4
Number Of Participants
16

Sites

Site Name
Noe LGA Gesundheit Region Mitte GmbH
Department Name
Klinische Abteilung für Innere Medizin 1, Hämatoonkologie
Contact Person Name
Petra Pichler
Site Name
SCRI CCCIT Ges.m.b.H.
Department Name
Uniklinikum Salzburg, Universitätsklinik für Innere Medizin III der PMU
Contact Person Name
Michael Leisch
Contact Person Email
m.leisch@salk.at
Site Name
Medical University Of Vienna
Department Name
Universitätsklinik für Innere Medizin I, Klinische Abteilung für Hämatologie und Hämostaseologie
Contact Person Name
Maria Krauth
Contact Person Email
maria.krauth@meduniwien.ac.at
Site Name
Ordensklinikum Linz GmbH
Department Name
Hämatologie mit Stammzelltransplantation, Hämostaseologie und medizinische Onkologie
Contact Person Name
Irene Strassl

Czechia

Earliest CTIS Part Ii Submission Date
07-10-2024
Latest Decision Or Authorization Date
17-02-2026
Processing Time Days
498
Number Of Sites
2
Number Of Participants
8

Sites

Site Name
Fakultni Nemocnice Brno
Department Name
Interní hematologická a onkologická klinika
Contact Person Name
Luděk Pour
Contact Person Email
pour.ludek@fnbrno.cz
Site Name
Fakultni Nemocnice Ostrava
Department Name
Klinika hematoonkologie
Contact Person Name
Roman Hájek
Contact Person Email
roman.hajek@fno.cz

Belgium

Earliest CTIS Part Ii Submission Date
16-10-2024
Latest Decision Or Authorization Date
16-02-2026
Processing Time Days
488
Number Of Sites
4
Number Of Participants
16

Sites

Site Name
Universitair Ziekenhuis Gent
Department Name
Hematology Department
Contact Person Name
Nicolas Kint
Contact Person Email
nikolas.kint@uzgent.be
Site Name
Cliniques Universitaires Saint-Luc
Department Name
Hematology Department
Contact Person Name
Marie-Christiane Vekemans
Site Name
UZ Leuven
Department Name
Hematology Department
Contact Person Name
Koen Debackere
Contact Person Email
koen.debackere@uzleuven.be
Site Name
Antwerp University Hospital
Department Name
Hematology Department
Contact Person Name
Sébastien Anguille
Contact Person Email
Sebastien.Anguille@uza.be

Spain

Earliest CTIS Part Ii Submission Date
12-08-2024
Latest Decision Or Authorization Date
19-02-2026
Processing Time Days
556
Number Of Sites
11
Number Of Participants
40

Sites

Site Name
Institut Catala D'oncologia
Department Name
Hematology
Contact Person Name
Albert Oriol Rocafiguera
Site Name
Hospital Universitario De Salamanca
Department Name
Hematology
Contact Person Name
Maria Victoria Mateos
Contact Person Email
mvmateos@usal.es
Site Name
Institut Catala D'oncologia (L'hospitalet)
Department Name
Hematology
Contact Person Name
Anna Sureda
Contact Person Email
asureda@iconcologia.net
Site Name
Clinica Universidad De Navarra
Department Name
Hematology
Contact Person Name
Paula Rodriguez Otero
Contact Person Email
paurodriguez@unav.es
Site Name
Hospital Universitario Y Politecnico La Fe
Department Name
Hematology
Contact Person Name
Javier De la Rubia Comos
Contact Person Email
delarubia_jav@gva.es
Site Name
University Clinical Hospital Virgen De La Arrixaca
Department Name
Hematology
Contact Person Name
Valentin Cabañas Perianes
Contact Person Email
valentin.cabanas@gmail.com
Site Name
Hospital Universitario Ramon Y Cajal
Department Name
Hematology
Contact Person Name
Javier Lopez Jimenez
Contact Person Email
jlopezj.hrc@salud.madrid.org
Site Name
University Hospital Virgen Del Rocio S.L.
Department Name
Hematology
Contact Person Name
Juan Luis Reguera Ortega
Contact Person Email
juanlu_jlr@hotmail.com
Site Name
Hospital Clinic De Barcelona
Department Name
Hematology
Contact Person Name
Carlos Fernandez de Larrea
Contact Person Email
CFERNAN1@clinic.cat
Site Name
Hospital Universitario 12 De Octubre
Department Name
Hematology
Contact Person Name
Joaquín Martínez López
Contact Person Email
jmarti01@ucm.es
Site Name
Hospital Universitario Marques De Valdecilla
Department Name
Hematology
Contact Person Name
Enrique Ocio San Miguel
Contact Person Email
enriquem.ocio@unican.es

Netherlands

Earliest CTIS Part Ii Submission Date
12-08-2024
Latest Decision Or Authorization Date
16-02-2026
Processing Time Days
553
Number Of Sites
3
Number Of Participants
12

Sites

Site Name
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Department Name
Hematology
Contact Person Name
Ruth Wester
Contact Person Email
r.wester@erasmusmc.nl
Site Name
Stichting Amsterdam UMC
Department Name
Hematology
Contact Person Name
Niels Van de Donk
Contact Person Email
hematology@amsterdamumc.nl
Site Name
Universitair Medisch Centrum Groningen
Department Name
Hematology
Contact Person Name
Wilfried Roeloffzen

Poland

Earliest CTIS Part Ii Submission Date
12-11-2024
Latest Decision Or Authorization Date
22-02-2026
Processing Time Days
467
Number Of Sites
4
Number Of Participants
16

Sites

Site Name
Uniwersyteckie Centrum Kliniczne Warszawskiego Uniwersytetu Medycznego
Department Name
Centralny Szpital Kliniczny, Klinika Hematologii, Transplantologii i Chorób Wewnętrznych
Contact Person Name
Grzegorz Basak
Contact Person Email
Grzegorz.basak@gmail.com
Site Name
Uniwersytecki Szpital Kliniczny Im. Jana Mikulicza-Radeckiego We Wroclawiu
Department Name
Klinika Hematologii, Terapii Komórkowych i Chorób Wewnętrznych
Contact Person Name
Tomasz Wróbel
Contact Person Email
tomasz.wrobel@usk.wroc.pl
Site Name
Uniwersytecki Szpital Kliniczny W Poznaniu
Contact Person Name
Dominik Dytfeld
Contact Person Email
dytfeld@me.com
Site Name
Instytut Hematologii I Transfuzjologii
Contact Person Name
Ewa Lech-Marańda
Contact Person Email
emaranda@ihit.waw.pl

France

Earliest CTIS Part Ii Submission Date
20-09-2024
Latest Decision Or Authorization Date
16-02-2026
Processing Time Days
514
Number Of Sites
10
Number Of Participants
40

Sites

Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
Service d’Hématologie Clinque
Contact Person Name
Cyrille TOUZEAU
Contact Person Email
cyrille.touzeau@chu-nantes.fr
Site Name
Hospices Civils De Lyon
Department Name
Service d’Hématologie
Contact Person Name
Lionel KARLIN
Contact Person Email
lionel.karlin@chu-lyon.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Service d’Immuno-Hématologie
Contact Person Name
Bertrand ARNULF
Contact Person Email
bertrand.arnulf@sls.aphp.fr
Site Name
Centre Hospitalier Universitaire De Toulouse
Department Name
Service d‘Hématologie
Contact Person Name
Aurore PERROT
Contact Person Email
perrot.aurore@iuct-oncopole.fr
Site Name
Centre Hospitalier Universitaire De Rennes
Department Name
Service d’Hématologie
Contact Person Name
Pierre DAUFRESNE
Contact Person Email
pierre.daufresne@chu-rennes.fr
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
Service des Maladies du sang
Contact Person Name
Salomon MANIER
Contact Person Email
salomon.manier@chru-lille.fr
Site Name
Centre Hospitalier Universitaire De Montpellier
Department Name
Service d’Hématologie clinique
Contact Person Name
Laure VINCENT
Contact Person Email
l-vincent@chu-montpellier.fr
Site Name
Centre Hospitalier Universitaire De Poitiers
Department Name
Service d’Hématologie et Thérapie Cellulaire
Contact Person Name
Xavier LELEU
Contact Person Email
xavier.leleu@chu-poitiers.fr
Site Name
Institut Paoli Calmettes
Department Name
Service d’Hématologie
Contact Person Name
Jean-Marc SCHIANO DE COLELLA
Contact Person Email
schianojm@ipc.unicancer.fr
Site Name
Assistance Publique Hopitaux De Paris (184 Rue Du Faubourg Saint Antoine)
Department Name
Département de Thérapie Cellulaire et Hématologie Clinique
Contact Person Name
Mohamad MOHTY
Contact Person Email
mohamad.mohty@inserm.fr

Sponsor

Primary sponsor

Full Name
Kite Pharma Inc.
Organisation Type
Pharmaceutical company
Country Of Registered Address
United States

Contract research organisations

Name
PPD Development LP
Responsibilities
Full service CRO for iMM-3: management of trial conduct, regulatory/start-up activities, central file preparation and maintenance, site management, and project management

Third parties

  • {"country":"United States","full_name":"PPD Development LP","duties_or_roles":"Full service CRO for iMM-3: management of trial conduct, regulatory/start-up activities, central file preparation and maintenance, site management, and project management","organisation_type":"Industry"}
  • {"country":"United States","full_name":"Signant Health Global LLC","duties_or_roles":"IXRS and randomization system","organisation_type":"Pharmaceutical company"}
  • {"country":"Switzerland","full_name":"Labcorp Central Laboratory Services SARL","duties_or_roles":"Central laboratory","organisation_type":"Pharmaceutical company"}
  • {"country":"United States","full_name":"Medidata","duties_or_roles":"Desk support for sites","organisation_type":"Non-Pharmaceutical company"}

Investigational products

Investigational Product Name
Anitocabtagene autoleucel
Active Substance
ANITOCABTAGENE AUTOLEUCEL
Modality
Cell therapy
Routes Of Administration
INTRAVENOUS
Route
Intravenous
Authorisation Status
Not authorised (prodAuthStatus: 1)
Combination Treatment
Yes

Related trials

Other published trials that may interest you.